96 related articles for article (PubMed ID: 22623170)
1. Intravenous dosing conditions may affect systemic clearance for highly lipophilic drugs: implications for lymphatic transport and absolute bioavailability studies.
Caliph SM; Trevaskis NL; Charman WN; Porter CJ
J Pharm Sci; 2012 Sep; 101(9):3540-6. PubMed ID: 22623170
[TBL] [Abstract][Full Text] [Related]
2. Effect of short-, medium-, and long-chain fatty acid-based vehicles on the absolute oral bioavailability and intestinal lymphatic transport of halofantrine and assessment of mass balance in lymph-cannulated and non-cannulated rats.
Caliph SM; Charman WN; Porter CJ
J Pharm Sci; 2000 Aug; 89(8):1073-84. PubMed ID: 10906731
[TBL] [Abstract][Full Text] [Related]
3. The impact of lymphatic transport on the systemic disposition of lipophilic drugs.
Caliph SM; Cao E; Bulitta JB; Hu L; Han S; Porter CJ; Trevaskis NL
J Pharm Sci; 2013 Jul; 102(7):2395-408. PubMed ID: 23696002
[TBL] [Abstract][Full Text] [Related]
4. The influence of lipids on stereoselective pharmacokinetics of halofantrine: Important implications in food-effect studies involving drugs that bind to lipoproteins.
Brocks DR; Wasan KM
J Pharm Sci; 2002 Aug; 91(8):1817-26. PubMed ID: 12115809
[TBL] [Abstract][Full Text] [Related]
5. Lymphatic transport of Methylnortestosterone undecanoate (MU) and the bioavailability of methylnortestosterone are highly sensitive to the mass of coadministered lipid after oral administration of MU.
White KL; Nguyen G; Charman WN; Edwards GA; Faassen WA; Porter CJ
J Pharmacol Exp Ther; 2009 Nov; 331(2):700-9. PubMed ID: 19696095
[TBL] [Abstract][Full Text] [Related]
6. Lymphatic transport of halofantrine in the triple-cannulated anesthetized rat model: effect of lipid vehicle dispersion.
Porter CJ; Charman SA; Charman WN
J Pharm Sci; 1996 Apr; 85(4):351-6. PubMed ID: 8901067
[TBL] [Abstract][Full Text] [Related]
7. Intestinal lymphatic transport of halofantrine in rats assessed using a chylomicron flow blocking approach: the influence of polysorbate 60 and 80.
Lind ML; Jacobsen J; Holm R; Müllertz A
Eur J Pharm Sci; 2008 Oct; 35(3):211-8. PubMed ID: 18675904
[TBL] [Abstract][Full Text] [Related]
8. Association of halofantrine with postprandially derived plasma lipoproteins decreases its clearance relative to administration in the fasted state.
Humberstone AJ; Porter CJ; Edwards GA; Charman WN
J Pharm Sci; 1998 Aug; 87(8):936-42. PubMed ID: 9687337
[TBL] [Abstract][Full Text] [Related]
9. Comparison of total oral bioavailability and the lymphatic transport of halofantrine from three different unsaturated triglycerides in lymph-cannulated conscious rats.
Holm R; Müllertz A; Christensen E; Høy CE; Kristensen HG
Eur J Pharm Sci; 2001 Dec; 14(4):331-7. PubMed ID: 11684408
[TBL] [Abstract][Full Text] [Related]
10. An examination of the interplay between enterocyte-based metabolism and lymphatic drug transport in the rat.
Trevaskis NL; Porter CJ; Charman WN
Drug Metab Dispos; 2006 May; 34(5):729-33. PubMed ID: 16467133
[TBL] [Abstract][Full Text] [Related]
11. A mouse model to evaluate the impact of species, sex, and lipid load on lymphatic drug transport.
Trevaskis NL; Caliph SM; Nguyen G; Tso P; Charman WN; Porter CJ
Pharm Res; 2013 Dec; 30(12):3254-70. PubMed ID: 23430484
[TBL] [Abstract][Full Text] [Related]
12. Influence of the type of surfactant and the degree of dispersion on the lymphatic transport of halofantrine in conscious rats.
Karpf DM; Holm R; Kristensen HG; Müllertz A
Pharm Res; 2004 Aug; 21(8):1413-8. PubMed ID: 15359576
[TBL] [Abstract][Full Text] [Related]
13. Enhanced oral absorption of halofantrine enantiomers after encapsulation in a proliposomal formulation.
Brocks DR; Betageri GV
J Pharm Pharmacol; 2002 Aug; 54(8):1049-53. PubMed ID: 12195818
[TBL] [Abstract][Full Text] [Related]
14. A physicochemical basis for the extensive intestinal lymphatic transport of a poorly lipid soluble antimalarial, halofantrine hydrochloride, after postprandial administration to dogs.
Khoo SM; Prankerd RJ; Edwards GA; Porter CJ; Charman WN
J Pharm Sci; 2002 Mar; 91(3):647-59. PubMed ID: 11920750
[TBL] [Abstract][Full Text] [Related]
15. A conscious dog model for assessing the absorption, enterocyte-based metabolism, and intestinal lymphatic transport of halofantrine.
Khoo SM; Edwards GA; Porter CJ; Charman WN
J Pharm Sci; 2001 Oct; 90(10):1599-607. PubMed ID: 11745718
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the lymphatic transport of halofantrine administered in disperse systems containing three different unsaturated fatty acids.
Holm R; Müllertz A; Pedersen GP; Kristensen HG
Pharm Res; 2001 Sep; 18(9):1299-304. PubMed ID: 11683243
[TBL] [Abstract][Full Text] [Related]
17. Intestinal lymphatic transport of halofantrine occurs after oral administration of a unit-dose lipid-based formulation to fasted dogs.
Khoo SM; Shackleford DM; Porter CJ; Edwards GA; Charman WN
Pharm Res; 2003 Sep; 20(9):1460-5. PubMed ID: 14567642
[TBL] [Abstract][Full Text] [Related]
18. A physicochemical basis for the effect of food on the absolute oral bioavailability of halofantrine.
Humberstone AJ; Porter CJ; Charman WN
J Pharm Sci; 1996 May; 85(5):525-9. PubMed ID: 8742945
[TBL] [Abstract][Full Text] [Related]
19. The Effect of Digestion and Drug Load on Halofantrine Absorption from Self-nanoemulsifying Drug Delivery System (SNEDDS).
Michaelsen MH; Wasan KM; Sivak O; Müllertz A; Rades T
AAPS J; 2016 Jan; 18(1):180-6. PubMed ID: 26486790
[TBL] [Abstract][Full Text] [Related]
20. Lymphatic transport of halofantrine in the conscious rat when administered as either the free base or the hydrochloride salt: effect of lipid class and lipid vehicle dispersion.
Porter CJ; Charman SA; Humberstone AJ; Charman WN
J Pharm Sci; 1996 Apr; 85(4):357-61. PubMed ID: 8901068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]